Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

464.600
-9.800-2.07%
Volume:203.92K
Turnover:94.65M
Market Cap:111.04B
PE:-239.96
High:473.800
Open:465.200
Low:459.800
Close:474.400
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.99
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.936
ROE:2.92%
ROA:0.03%
PB:17.80
PE(LYR):-239.96
PS:45.55

Loading ...

MerckRapidly Advances ADC+IO 2.0 Strategy with SKB BIO's TROP2 ADC Joint PD-1/VEGF Bispecific Antibody Phase II Trial

Deep News
·
Jul 29

Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA IND Approval for Skb565

Reuters
·
Jul 27

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-Payload ADC Skb565

THOMSON REUTERS
·
Jul 27

SKB BIO Receives NMPA Approval for Clinical Trial of Novel Dual-Load ADC Drug

Stock News
·
Jul 27

Kelun-Biotech Wins China IND Clearance for Skb565 in Advanced Solid Tumors

Reuters
·
Jul 27

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives Nmpa Ind Approval for Skb565 for Advanced Solid Tumors

THOMSON REUTERS
·
Jul 27

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.62% at Open, Investment Banks Raise Target Prices Amid Institutional Accumulation Wave

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.08% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Institutional Buying Wave

Market Focus
·
Jul 21

JPMorgan Raises Price Target for SKB BIO to HK$648, Maintains Overweight Rating

Deep News
·
Jul 20

Movement Alert|Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound

Market Focus
·
Jul 20

Movement Alert|Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness

Market Focus
·
Jul 17

HBM Holdings's Asthma Drug Candidate Secures China's Approval

MT Newswires Live
·
Jul 16

Goldman Sachs Reiterates Buy Rating on Kelun-Bota Biopharma, Raises Target Price to HK$582.95

Deep News
·
Jul 16

Movement Alert|Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally

Market Focus
·
Jul 16

Merck Rises After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

Reuters
·
Jul 15

SKB BIO Secures HK$2.7 Billion Placement to Fund R&D, Total Post-IPO Fundraising Approaches HK$7 Billion

Deep News
·
Jul 15

China NMPA Clears Kelun-biotech, Harbour Biomed Asthma IND for Skb575/hbm7575

Reuters
·
Jul 15

Hbm Holdings - Hbm7575 Co-developed by Harbour Biomed and Kelun-biotech

THOMSON REUTERS
·
Jul 15

Kelun-biotech and Harbour Biomed Announce Nmpa Approval of Ind Application for Skb575/hbm7575 for the Treatment of Asthma

THOMSON REUTERS
·
Jul 15